InvestorsHub Logo
Followers 87
Posts 6614
Boards Moderated 1
Alias Born 09/18/2009

Re: cowtown jay post# 42114

Friday, 03/22/2024 4:14:25 PM

Friday, March 22, 2024 4:14:25 PM

Post# of 42645
"A PREP Act declaration is specifically for the purpose of providing immunity from liability"

https://aspr.hhs.gov/legal/PREPact/Pages/default.aspx

It only makes sense to have an alternative, traditional vaccine, available to meet healthcare demands, in the event that mRNA vaccine manufacturers withdraw from the market, when PREP Act protection expires. The only traditional vaccine approved for use in the US is the Novavax vaccine. If the safety and efficacy of that vaccine proves to be enhanced by Humanigen's patented methodology, using lenzilumab, then the company needs to be prepared to meet that demand.

Not only is the subject germane, the issue is critical. We cannot let a highly lethal virus attach to receptor cells, and if they do, we need to combat the effects of that infection vigorously and effectively, using lenzilumab, in both processes. Lenzilumab showed outstanding results when administered early. The LIVE-AIR trial met the primary endpoint, and those results have been peer-reviewed by both Lancet and Thorax. The company has a history of treatment data for the product, even preceding Covid.